Homozygous carriers of the G allele of rs4664447 of the glucagon gene (GCG) are characterised by decreased fasting and stimulated levels of insulin, glucagon and glucagon-like peptide (GLP)-1 by Torekov, S S et al.
ARTICLE
Homozygous carriers of the G allele of rs4664447
of the glucagon gene (GCG) are characterised
by decreased fasting and stimulated levels of insulin,
glucagon and glucagon-like peptide (GLP)-1
S. S. Torekov & L. Ma & N. Grarup & B. Hartmann & I. A. Hainerová & U. Kielgast & H. Kissow &
M. Rosenkilde & GIANT Consortium & J. Lebl & D. R. Witte & T. Jørgensen & A. Sandbaek &
T. Lauritzen & O. D. Madsen & J. Wang & A. Linneberg &
S. Madsbad & J. J. Holst & T. Hansen & O. Pedersen
Abstract
Aims/hypothesis The glucagon gene (GCG) encodes sever-
al hormones important for energy metabolism: glucagon,
oxyntomodulin and glucagon-like peptide (GLP)-1 and -2.
Variants in GCG may associate with type 2 diabetes, obesity
and/or related metabolic traits.
Methods GCG was re-sequenced as a candidate gene in
865 European individuals. Twenty-nine variants were
identified. Four variants that were considered to have a
likelihood for altered functionality: rs4664447, rs7581952,
Ile158Val and Trp169Ter, were genotyped in 17,584 Danes.
Results When examined in 5,760 treatment-naive individuals,
homozygous carriers of the low frequency (minor allele
frequency 2.3%) G allele of rs4664447, predicted to disrupt
an essential splice enhancer binding site, had lower levels of
fasting plasma glucose (mean±SD, 4.8±1.2 vs 5.5±
0.8 mmol/l, p=0.004); fasting serum insulin (22±14 vs
42±27 pmol/l, p=0.04); glucose-stimulated serum insulin
(159±83 vs 290±183 pmol/l, p=0.01) and adult height
(165±10 vs 172±9 cm, p=0.0009) compared with A allele
carriers. During oral glucose tolerance and hyperglycae-
mic arginine stimulation tests, the plasma AUC for GLP-1
(730±69 vs 1,334±288 pmol/l×min, p=0.0002) and basal
and stimulated levels of serum insulin and plasma glucagon
were ∼50% decreased (p<0.001) among three homozy-
gous carriers compared with nine matched wild-type
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carriers. rs7581952, Ile158Val and Trp169Ter (where ‘Ter’
indicates ‘termination’) variants of GCG did not significantly
associate or co-segregate with the metabolic traits examined.
Conclusions/interpretation Re-sequencing of GCG revealed
a low frequency intronic variant, rs4664447, and follow-up
physiological studies suggest that this variant in homozygous
form may cause decreased fasting and stimulated levels of
insulin, glucagon and GLP-1. Overall, our findings suggest
that variation in GCG has no major impact on carbohydrate
metabolism in the study populations examined.
Keywords Genetics of type 2 diabetes . Insulin secretion in
vivo . Insulin sensitivity and resistance . Islets . Metabolic
physiology in vivo .Monogenic forms of diabetes
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Introduction
For the past several years most studies of the genetics of
obesity and type 2 diabetes have been based on the HapMap
resource of sequence variation [1], forming the basis for
genome-wide association studies (GWAS). While HapMap
offers good proxies for most common single nucleotide
polymorphisms (SNPs) with a frequency above 5%, the
coverage rapidly declines for alleles with lower frequency
[2]. In order to identify disease-associated low frequency and
rare variants, we need to re-sequence the genes or, ideally,
the whole genome in thousands of cases and controls. The
glucagon gene (GCG) located on chromosome 2q24.2
consists of six exons and encodes several proteins crucial
for energy metabolism, i.e. glucagon, glucagon-like peptide
(GLP)-1 and −2, and oxyntomodulin [3]. To date no study on
large-scale sequencing of GCG has been published. In light
of the crucial role of GCG in energy metabolism, we
hypothesised that low frequency variants of GCG are
associated with diabetes, obesity and/or related metabolic
intermediary quantitative traits. Therefore, we performed a
large-scale candidate gene study of GCG.
Methods
DNA analysis of GCG Genomic DNA was isolated from
human leucocytes using standard methods. Primer3 was
used to design primers targeting the coding, exon–intron
boundary, and conserved regions of GCG (NCBI: X03991,
gi31786). The conserved regions were selected by satisfy-
ing: (1) BlastN E-value <1×10−20; (2) length >100 bp; (3)
existence of homology sequences at least in two of Bos
taurus, Rattus norvegicus, Mus musculus and Gallus gallus.
Nine segments were obtained by PCR amplifier,
corresponding to six exons (plus the exon–intron boundary)
and three conserved regions (Table 1). The amplified
samples were subject to multiple direct sequencing using
an ABI 3730 platform (Life Technologies, Carlsbad, CA,
USA) following the standard protocol advised by the
manufacturer. The sequences of the nine fragments were
aligned together, and PolyPhred [4] and Consed [5] were
employed to detect variants among samples. Variants were
considered true when consensus was obtained between
multiple repeated sequenced samples. Genotyping of the
polymorphisms was performed using KASPar allelic dis-
crimination (KBioscience, Hoddesdon, UK). Discordance
between 1,479 random duplicate samples was 0% and the
genotyping success rate was >99.5% for all variants. All
variants obeyed Hardy–Weinberg equilibrium (p>0.2).
Study population for mutation detection
1. In order to identify low frequency SNPs in the general
population, GCG was re-sequenced in 384 randomly
selected unrelated middle-aged Danish individuals,
45% men, aged 45±7 years, BMI 26.8±5.0 kg/m2,
randomly recruited in the Inter99 study [6]; 35 of these
individuals had type 2 diabetes.
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2. In order to identify GCG variants potentially associated
with early-onset obesity, GCG was re-sequenced in 289
(157 girls, 132 boys) Czech children and adolescents
with early-onset obesity aged 1–18 years. Early-onset
obesity was defined as obesity observed before the age
of 11 years and with BMI (kilograms per square metre),
retrospectively evaluated, exceeding the 97th percentile
for sex and age according to Czech national references.
The mean age at obesity onset was 4.9±3.1 years
(range 0.5–11.0 years) [7].
3. In order to identify GCG variants potentially associated
with inheritance of adult-onset obesity and type 2
diabetes, GCG was re-sequenced in 96 (50 women, 46
men) obese Danish individuals, aged 50±15 years,
BMI 36.4±5.1 kg/m2, all recruited from obese families
with type 2 diabetes at Steno Diabetes Center in
Copenhagen.
4. In order to identify GCG variants potentially associated
with inheritance of early-onset diabetes, GCG was re-
sequenced in 86 Danish and 10 Czech patients (55
Table 1 GCG variants discovered in 865 European individuals
SNP
no.
Variant identified
in ampliconb
containing
rs number Genomic position
(NCBI Build 37)
Location relative
to exons
n
participants
Heterozygous
frequency (%)
Identified
in study
group
Predicted
functionality
score (1 [low]–5
[high])
1 Conserved region 1 163006577 −1052A/G rel. ATG site 6 0.7 1 1
2 Conserved region 1 163006519 −827T/C rel. ATG site 1 0.1 1 1
3 Conserved region 1 163006515 −827G/A rel. ATG site 2 0.2 2 and 3 1
4 Conserved region 1 163006150 −462G/A rel. ATG site 2 0.2 1 and 3 1
5 Conserved region 1 163006000 −312 A/T rel. ATG site 1 0.1 1 1
6 Conserved region 1 163005875 −186 A/G rel. ATG site 1 0.1 1 1
7 Exon 2 rs5645/rs13306376 163005674 Tyr5Tyr 50 5.8 1–4 1
8 Exon 2 163005649 Leu14Leu C/T 1 0.1 2 1
9 Conserved region 2 163004525 −501T/G rel. exon 3 1 0.1 1 1
10 Conserved region 2 163004459 −4358G/A rel. exon 3 1 0.1 3 1
11 Conserved region 2 163004410 −4407T/C rel. exon3 1 0.1 2 1
12 Conserved region 2 163004291 −255G/A rel exon 3 1 0.1 2 1
13 Exon3 163003985 Pro44Pro T/C 1 0.1 1 1
14 Exon3 rs11552330 163003961 Arg52Arg 1 0.1 1 1
15 Exon3 rs5649 163003858 +5 rel. exon 3 4 0.5 1 1
16 Conserved region 3 rs4664447a 163003191 +671 A/G rel. exon 3 50 5.8 1–4 4
17 Conserved region 3 163003173 +689G/A rel. exon3 1 0.1 3 1
18 Exon 4 163002256 −71T/C rel exon 4 20 2.3 1–3 1
19 Exon 4 163001920 +128G/A rel. exon 4 1 0.1 1 1
20 Exon 4 163001905 +143T/A rel. exon 4 1 0.1 4 1
21 Exon 5 rs7581952a 163000856 −176T/G rel. Exon 5 44 5.1 1–4 2
22 Exon 5 163000768 −88 A/G rel. exon 5 1 0.1 1 1
23 Exon 5 163000601 Ile158Vala 2 0.2 1 4
24 Exon 5 163000564 Trp169Tera 1 0.1 4 5
25 Exon 5 163000460 +73C/T rel. exon 5 1 0.1 2 1
26 Exon 5 163000351 +192G/T rel. exon 5 1 0.1 1 1
27 Exon 5 163000307 +226 A/G rel. exon 5 1 0.1 2 1
28 Exon 5 163000301 +232 A/G rel. exon 5 4 0.5 1, 2 and 4 1
29 Exon 6 162999704 +175T/A rel exon 6 1 0.1 1 1
The individuals were from the following study groups: (1) 384 middle-aged Danish people randomly picked from Inter99; (2) 289 obese Czech
children; (3) 96 obese adult Danes; and (4) 86 Danish and 10 Czech patients with early-onset non-autoimmune diabetes
rs5645 and rs4664447 were in complete LD (r2 = 1.0)
a Variants selected for large-scale genotyping
b Coordinates of amplicons (relative to X03991): exon 1, 535–698; conserved region 1, 2,840–3,500; exon 2, 3,289–3,770; conserved region 2,
4,841–5,244; exon 3, 5,262–5,603; conserved region 3, 5,810–6,400; exon 4, 7,043–7,476; exon 5, 8,683–8,826; exon 6, 9,481–10,050. No
variants were detected in exon 1. The genomic position on chromosome 2 is from NCBI Build 37
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women, 41 men) with onset of diabetes before the age
of 40 and with a family history of diabetes. None of the
patients had mutations in any of the known MODY
genes (MODY1–6); age 35±10 years, age of onset 25±
5 years, BMI 26.0±5 kg/m2.
Bioinformatics analyses and selection of variants for large-
scale genotyping Functionality of all identified variants was
predicted by FastSNP [8] and ESEFinder [9]. Variants were
scored from 1 (low predicted functionality) to 5 (high
predicted functionality) (Table 1). Based upon functionality
predictions, we chose to genotype rs4664447 (predicted
functionality 4, minor allele frequency [MAF] 2.4%),
rs7581952 (predicted functionality 2, MAF 2.3%), Ile158Val
(predicted functionality 4, MAF 0.2%) and Trp169Ter (‘Ter’
indicates ‘termination’; predicted functionality 5, very rare) in
17,584 Danes and to analyse for genotype–trait relationships.
In the initial screening of the 384 randomly selected
individuals from Inter99, rs4664447 and rs5645 were in
complete linkage disequilibrium (LD) (r2=1).
Study population for large-scale genotyping Trp169Ter,
Ile158Val, rs7581952, and rs4664447 were genotyped in
17,584 Danish individuals comprising the following.
1. The Inter99 sample of randomly collected middle-aged
Danish individuals examined at the Research Centre for
Prevention and Health [6], n=6,204, 3,070 men, 3,094
women, age 46±8 years, BMI 26.3±4.6 kg/m2). The
Inter99 study (ClinicalTrials.gov NCT00289237) is a
randomised multi-factorial intervention study aiming at
changing lifestyle to prevent cardiovascular disease and
diabetes in a free-living population examined over a 5-
year period.
2. A randomly recruited group of middle-aged glucose-
tolerant participants examined at Steno Diabetes Center
(n=521, 244 men, 277 women, age 57±10 years, BMI
25.8±3.7 kg/m2).
3. Type 2 diabetes patients sampled through the outpatient
clinic at Steno Diabetes Center (n=1,820, 1,117 men,
703 women, age 61±11 years, BMI 30.3±5.5 kg/m2).
4. The ADDITION (Anglo-Danish-Dutch Study of Intensive
Treatment and Complication Prevention in Type 2
Diabetic Patients Identified by Screening in Primary Care)
Denmark screening cohort (n=8,662, 4,729 men, 3,933
women, age 60±7 years, BMI 28.6±4.9 kg/m2) sampled
by the Department of General Practice at the University
of Aarhus [10]. The ADDITION Denmark screening
cohort (ClinicalTrials.gov NCT00237548) includes par-
ticipants who were recruited via a stepwise strategy
based on a risk questionnaire followed by measurements
of random blood glucose, HbA1c, and fasting and OGTT
plasma glucose to clinically diagnose diabetes.
5. A randomly recruited sample of young healthy partic-
ipants recruited from the Steno Diabetes Centre
(Gentofte, Denmark): UNG92 (n=377, 186 men, 191
women, age 25±4 years, BMI 23.6±3.7 kg/m2) [11].
Study groups 1 and 2 underwent a standard 75 g OGTT,
and study group 5 underwent an IVGTT in combination
with tolbutamide stimulation as described [11].
Case–control studies of type 2 diabetes were carried out
in 3,778 type 2 diabetes patients (1,820 patients recruited at
Steno Diabetes Center, 340 patients from the Inter99
cohort, and 1,618 patients from the Danish ADDITION
Study) and 5,043 glucose-tolerant participants (521 indi-
viduals recruited at Steno Diabetes Center and 4,522
individuals from Inter99). Studies of quantitative glucose
related traits were carried out in treatment-naive individuals
from the Inter99 Study, excluding the 340 patients
diagnosed with and treated for type 2 diabetes. Case
(BMI≥30 kg/m2)/control (BMI<25 kg/m2) studies of
obesity and studies of quantitative obesity-related traits
were performed in the pooled combined study sample of
17,584 Danish individuals.
The actual number of individuals genotyped for each
variant is given in the respective tables. There was no
overlap between sequenced study samples and genotyped
study samples, apart from the 384 randomly selected
individuals from the Inter99 Study. Informed written
consent was obtained from all individuals before participa-
tion. The study was approved by the Ethical Committee of
Copenhagen County and was in accordance with the
principles of the Helsinki Declaration. Type 2 diabetes
was defined according to the WHO recommendations [12].
Biochemical and anthropometric measures Height and
body weight were measured while participants were
wearing light indoor clothes and without shoes, and BMI
was calculated as weight in kilograms/(height in metres)2.
Waist circumference was measured in the standing position
midway between the iliac crest and the lower costal margin.
Blood samples were drawn after a 12 h overnight fast.
Plasma glucose was measured by a glucose oxidase method
(Granutest; Merck, Darmstadt, Germany) with a detection
limit of 0.11 mmol/l and intra- and inter-assay coefficients
of variation of <0.8% and <1.4%, respectively. Radio-
immunological determination of fully processed glucagon
was performed using a specific assay as described [13]. The
analytical detection limit was 1 pmol/l and intra- and inter-
assay coefficients of variation were <6% and <15%,
respectively. Total plasma GLP-1 was assayed by radioim-
munoassay as described previously [14]. The assay has a
detection limit of 1 pmol/l and intra- and inter-assay
coefficients of variation are <6% and <15%, respectively.
Serum insulin [excluding des (31,32) and intact proinsulin]
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was measured using the AutoDELFIA insulin kit (Perkin-
Elmer, Wallac, Turku, Finland). Total intra- and inter-assay
coefficients of variation were <3.2% and 4.5%, respectively.
The analytical detection limit was 3 pmol/l.
Methods for additional physiological characterisation of
rs4664447 carriers Three participants (two men and one
woman, age 50–65 years, BMI 18.6–25.9 kg/m2) who were
homozygous carriers of rs4664447 were available for
additional phenotype studies. For each carrier, three BMI,
age and sex matched controls (wild-type carriers) (nine in
total, three women, six men, mean age 54±7 years, mean
BMI 24.7±3.3 kg/m2) were invited for additional metabolic
characterisation at the Steno Diabetes Center.
Oral glucose tolerance test After an overnight fast, blood
samples for measurement of plasma glucose, serum insulin,
serum C-peptide, plasma GLP-1 and plasma glucagon were
taken prior to a standard 75 g OGTT. Blood sampling was
repeated every 15min until 180min after the start of the OGTT.
Glucose-dependent arginine stimulation test The test was
performed as described [15] and used to measure the acute
insulin and glucagon responses to intravenous arginine
injection at the fasting plasma glucose level and at glucose
concentrations clamped at 14 and at 25 mmol/l, respectively.
After an overnight fast, blood samples for measurement of
serum insulin, serum C-peptide, plasma GLP-1, and plasma
glucagon were taken prior to arginine injection and eight
times during the following 30 min in the fasting state and
with glucose concentrations clamped at 14 and at 25 mmol/l,
respectively. There was a 2.5 h resting period between the
clamps at 14 and at 25 mmol/l of plasma glucose.
Statistical analysis Case–control studies were performed
by applying logistic regression including adjustments for
sex, age and BMI (for type 2 diabetes analyses) to examine
differences in genotype distributions between affected and
unaffected individuals. Studies of the Ile158Val variant
were calculated for the dominant model (wild-type vs
heterozygote+homozygote, where wild-type is the major
allele), as it was too rare to calculate the OR for the additive
and recessive model. The recessive model (wild-type+
heterozygote vs homozygote), was chosen relevant for the
other variants. The additive model was added as a reference
in comparison with the studies in large consortia as these
only show additive models. To test for quantitative trait
differences between genotype groups, a general linear
model was used including adjustments for sex, age and
BMI when appropriate. We did not find any evidence of
population stratification when we applied 39 unlinked
markers using the Structure program [16]. Furthermore,
we did not detect any evidence of population stratification
among the study groups in the data set when adjusting for
the first principal component of Eigenstrat analysis among
11,150 individuals on whom we have sufficient SNP data to
perform Eigenstrat analysis [17]. Consequently, the study
groups were pooled for analysis. The incremental AUC was
calculated using the trapezoidal method. Insulinogenic
index and HOMA-IR were calculated as described [18].
During the OGTT, the disposition index was calculated as
insulinogenic index/HOMA-IR and during the intravenous
arginine stimulation test, the disposition index was calcu-
lated as acute insulin response to arginine stimulation (0–
10 min) (AIR0–10arginine)/HOMA-IR. Analyses were per-
formed with RGui version 2.8.0 and GraphPad Prism 5.
Statistical power estimations of case–control studies were
calculated in CaTS power calculator, version 0.02 (www.
sph.umich.edu/csg/abecasis/CaTS/index.html) and power
estimations of quantitative traits analyses were calculated in
PS power and sample size calculation version 3.0.34 (http://
ps-power-and-sample-size-calculation.software.informer.
com/download). Taking Bonferroni correction into consider-
ation (which is conservative in this case given the correlation
among the traits) leads to a significance level of p=0.0012.
Thus, only p values of 0.001 or less were considered
significant.
Results
By re-sequencing GCG in 853 Europeans, many of whom
had type 2 diabetes or were obese, we identified 29
different variants (Table 1). Four variants with a considered
likelihood for altered functionality: rs4664447, rs7581952,
Ile158Val and Trp169Ter were selected for large-scale
genotyping in a total of 17,584 Danish individuals and
investigated for association with obesity, type 2 diabetes
and metabolic traits (Fig. 1).
rs4664447 was not associated with type 2 diabetes
(Table 2). However, homozygous carriers of the G allele
of rs4664447 had lower fasting plasma glucose, lower
fasting and oral glucose-stimulated serum insulin, lower
insulinogenic index, lower HOMA-IR, higher Matsuda’s
insulin sensitivity, normal disposition index and shorter
adult height compared with A allele carriers when analysed
in 5,760 treatment-naive middle-aged individuals from the
Inter99 cohort (Table 3). With four GG carriers and 5756
AA and AG carriers and a difference in fasting mean serum
insulin of 20 pmol/l insulin and a standard deviation of 14
we have a statistical power of 82%, p<0.05. The
association with lower fasting plasma glucose was even
stronger when the analyses were restricted to the 4,370
glucose-tolerant people of Inter99, (AA, 5.3±0.4+AG, 5.3
±0.4 vs GG, 4.8±1.1 mmol/l glucose prec=0.00004, where
prec is the p value for the recessive model). During an
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OGTT, performed 10 years after the baseline investigation,
the AUC for plasma GLP-1 was significantly lower among
three homozygous carriers compared with nine matched
wild-type carriers (730±69 vs 1,334±288 pmol/l×min, p=
0.0002) (Fig. 2). During a glucose-dependent arginine
stimulation test, performed 10 years after the baseline
investigation, the AUCs for fully processed glucagon
during fasting and during the clamps at 14 and 25 mmol/l
glucose were significantly lower for the three homozygous
variant carriers compared with nine matched wild-type carriers
(1,013±39 vs 1,865±449 pmol/l×min glucagon, p=0.0004)
(Fig. 3). The AUCs for serum insulin levels were lower
during the arginine stimulation test among three homozygous
variant carriers compared with nine matched non-carriers
(51,831±6,351 vs 76,336±9,249 pmol/l×min, p=0.007)
(Fig. 3 and Table 4). With three GG carriers and nine matched
AA carriers we have a power above 80%, p<0.0005, to detect
the differences in insulin, GLP-1 and glucagon levels between
the two groups. In our combined study groups, involving
17,582 Danish individuals, homozygous GG carriers of this
Ile158Valine
Pancreas 
Small intestine 
1 3 GCG 2 3 4 5 6 2 
 53 Glucagon 72 
146 GLP-2 178 98 GLP-1 128 53 Oxyntomodulin 89 
1 
rs4664447 rs7581952  
Trp169Ter 
Fig. 1 Genomic structure of GCG and simplified processing of
proglucagon hormones. Top: black boxes are exons and grey boxes
are conserved inter-exon regions. Bottom: numbers refer to amino
acid number in the proglucagon peptide before cleavage, counting
from amino acid no. 1 in the signal peptide. Post-translational
processing of proglucagon in the pancreas by prohormone
convertase (PC) 2 yields glucagon, whereas processing in the
intestine by PC1 liberates oxyntomodulin, GLP-1 and GLP-2. The
approximate locations of genotyped variants are shown with
arrows
Table 2 Case–control studies of type 2 diabetes in relation to the Ile158Val, rs4664447, and rs7581952 variants in GCG
GCG variant n(men/women) Genotype distribution
Wt/He/Ho (%)
MAF (%) (95% CI) OR (95% CI) padd pdom prec
Ile158Val IleIle/IleVal/ValVal
Glucose-tolerant
individuals
4,768 (2,216/2,552) 4,750/18/0 (99.6/0.4/0) 0.2 (0.1, 0.3)
Patients with T2D 3,641 (2,167/1,474) 3,618/22/1 (99.3/0.6/0) 0.3 (0.2, 0.5) 1.83 (1.05, 3.9) 0.04 0.03
rs4664447 AA/GA/GG
Glucose-tolerant
individuals
4,882 (2,253/2,629) 4,657/221/4 (95.4/4.5/0.1) 2.3 (2.1, 2.7)
Patients with T2D 3,525 (2,089/1,436) 3,358/161/6 (95.3/4.6/0.2) 2.5 (2.1, 2.8) 1.05 (0.85, 1.28) 0.7 0.8 0.3
rs7581952 TT/TG/GG
Glucose-tolerant
individuals
4,825 (2,243/2,582) 4,606/221/2 (95.4/4.6/0) 2.3 (2, 2.7)
Patients with T2D 3,491 (2,073/1,418) 3,326/161/0 (95.3/4.6/0.1) 2.4 (2.1, 2.8) 1.04 (0.84, 1.28) 0.7 0.8 0.2
Data are number of individuals (men/women), divided into genotype groups (% in each group), frequencies of the minor allele (MAF) as percentages
(95% CI) and ORs (95% CI). Differences in genotype distribution were evaluated using logistic regression. p values were adjusted for age, BMI and
sex. The OR is calculated for the dominant model (wild-type [Wt] vs heterozygote [He]+homozygote [Ho]). Case–control studies of type 2
diabetes (T2D) were carried out in 3,778 type 2 diabetes patients (1,820 patients recruited at Steno Diabetes Center, 340 patients from the Inter99
cohort, and 1,618 patients from the Danish ADDITION study) and 5,043 glucose-tolerant participants (521 individuals recruited at Steno Diabetes
Center and 4,522 individuals from Inter99). The actual number of individuals successfully genotyped for each variant is given in the table
padd, pdom, prec, p values for additive, dominant and recessive models, respectively
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variant had decreased height and body weight (Table 5). GCG
rs4664447 was not associated with estimates of BMI-defined
obesity (ESM Table 1). No meta-analysis data according to a
recessive genetic model were available from the Meta-
Analyses of Glucose and Insulin Related Traits Consortium
(MAGIC) [19]. The variant was not associated with fasting
plasma glucose (p=0.8), fasting serum insulin (p=0.6) or
HOMA-IR (p=0.4) in meta-analysis data from MAGIC [19]
analysed in an additive model. The variant failed a cohort-
specific quality check in the Diabetes Genetics Replication
And Meta-analysis Consortium (DIAGRAM+) [20] analyses.
The 158Val variant was associated with a higher risk of
type 2 diabetes, OR 1.83 (95% CI 1.05, 3.9), p=0.03
(Table 2). The statistical power with 4,768 controls and
3,641 cases was 80% to detect an OR of 1.83 for this
variant (MAF of 0.03%) (CaTS power calculator). Hetero-
zygous carriers of 158Val tended to have lower fasting
serum insulin and insulinogenic index (p=0.06), and lower
weight (p=0.01) when analysed in 5,795 middle-aged
people from Inter99 (Table 6). Ile158Val was not associated
with measures of BMI-defined obesity (ESM Table 1). We
were unable to associate the 158Val variant with type 2
diabetes in DIAGRAM+ [20], since this variant was not
genotyped or imputed in DIAGRAM+ [20]. There were,
however, no significant differences in functional receptor
analyses and in intestinotrophic effect analyses between the
actions of wild-type GLP-2 and [Ile158Val]-GLP-2 (ESM
Fig. 1, ESM Table 2 and ESM Methods).
GCG rs7581952 was not associated with BMI-defined
obesity when examined in a case–control study of 10,223
individuals (ESM Table 1) or with BMI in 5,761 treatment-
naive people in the Inter99 Study (Table 7). However, in the
total group of 17,557 individuals, carriers of the minor G
allele of GCG rs7581952 had lower values of BMI, body
weight and waist circumference as compared with T allele
carriers when analysed applying a dominant and additive
genetic model (Table 5). In an attempt to replicate these
Table 3 Associations of rs4664447 in GCG with metabolic traits in treatment-naive individuals from the Inter99 cohort
Rs4664447 AA AG GG Estimatesrec (95% CI) padd pdom prec
Alleles (men/women) 5,495 (2,723/2,772) 261 (126/135) 4 (3/1)
Age (years) 46.1±7.9 47.0±8.5 43.9±7.6
Height (cm) 172.3±9.2 172.0±9.4 165.3±10.5 −11 (−17, −4.4) 0.4 0.7 0.0009
Weight (kg) 78.1±16 77.3±16.2 63.6±13.4 −18.1 (−4.2, −32.0) 0.2 0.3 0.01
BMI (kg/m2) 26.2±4.5 26.1±4.9 23.2±3.1 −3.2 (−7.5, 1.2) 0.4 0.5 0.2
Waist circumference (cm) 86.4±13.2 86.3±13.1 79.8±7.9 −9.4 (−21, 1.7) 0.6 0.7 0.09
Serum insulin 0 min (pmol/l) 41.8±27.8 42.6±28.1 22.3±14.1 −0.61 (−1.2, −0.034) 0.9 0.9 0.04
Serum insulin 30 min (pmol/l) 290.0±183 298.3±197.6 159.3±83.2 −0.58 (−1.1, −0.034) 0.9 0.7 0.01
Serum insulin 120 min (pmol/l) 216.7±210.9 218.2±216.6 95±22.2 −0.44 (−1.2, 0.34) 0.6 0.6 0.3
Plasma glucose 0 min (mmol/l) 5.5±0.8 5.6±0.7 4.8±1.2 −0.16 (−0.27, −0.054) 0.7 0.4 0.004
Plasma glucose 30 min (mmol/l) 8.7±1.9 8.8±1.9 9.4±2.1 0.073 (−0.12, 0.27) 0.5 0.6 0.5
Plasma glucose 120 min (mmol/l) 6.21±2.14 6.27±1.94 5.12±0.85 −0.13 (−0.42, 0.16) 0.8 0.8 0.4
HOMA-IR 10.6±8.0 10.9±8.0 5.0±4.1 −0.77 (−1.4, −0.15) 0.9 0.8 0.01
Matsuda’s insulin sensitivity 9.0±5.7 8.8±5.4 15.9±6.5 0.68 (0.097, 1.3) 0.8 0.7 0.02
Insulinogenic index 29.2±19.4 29.8±21.3 15.0±9.8 −0.63 (−1.2, −0.022) 0.8 1.0 0.04
Disposition index 3.6±2.8 3.7±3.1 4.5±4.3 0.15 (−0.58, 0.88) 0.8 0.8 0.7
Data are mean±SD
p values were shown for an additive (padd) (AAvs AG vs GG), dominant (pdom) (AAvs AG+GG) and a recessive model (prec) (AA+AG vs GG)
(wild-type+heterozygote vs homozygote). Calculated p values were adjusted for sex, age and BMI (when appropriate). Insulin and glucose values
were log10 transformed before analysis
Fig. 2 Plasma GLP-1 levels during an OGTT. Black circles: mutation
carriers (rs4664447 GG), n=3; white squares: non-mutation carriers
(rs4664447 AA) who are BMI, age and sex matched controls (wild-
types), n=9. pAUC=0.0002
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observations, rs7581952 was analysed using GIANT meta-
analysis data [21]. rs7581952 was not significantly associ-
ated with decreased BMI when analysed with an additive
model in 100,734 individuals (change in BMI per additional
G allele −0.03 kg/m2 (SE 0.02), p=0.2; GIANT consor-
tium). The variant failed a cohort-specific quality check in
DIAGRAM.
GCG Trp169Ter was initially identified in heterozygous
form in one person from the study population for mutation
detection in study group 4: onset of diabetes before the age
of 40 years and with a family history of diabetes (Table 1).
The family members of the carrier were genotyped for the
variant. No co-segregation of the variant with diabetes or
with measures of obesity was observed (ESM Fig. 2).
Furthermore, subsequently the variant was genotyped in the
large Danish sample of 17,584 people and was found in one
glucose-tolerant person (age 48 years, BMI 29.4 kg/m2)
with a distant family history of diabetes (the grandmother
on the father’s side and three of the father’s ten siblings had
diabetes); however, no DNAwas available from the family
members.
Discussion
The outcome of the present study of variation in an obvious
biological candidate gene, GCG, known to be involved in
multiple steps of metabolism, suggests that homozygous
carriers of the G allele of the low frequency GCG variant,
rs4664447, exhibit several altered metabolic traits. Thus,
homozygous carriers have ∼50% of the serum insulin levels
in the fasting state and following an oral glucose challenge,
and lower fasting plasma glucose and height as compared
with A allele carriers. The intronic rs4664447 is located in
the binding site of the splice enhancer serine/arginine-rich
splicing factor 1 isoform 2 (SF2/ASF), which interacts with
the spliceosome and ensures the accuracy of splicing.
Based upon in silico estimation, the variant is predicted to
disrupt this essential binding site, and is estimated to have
high functionality (risk 4 on a scale of 0–5). Furthermore,
the A allele is conserved among species and the variant is
positioned in a conserved region. We hypothesised that the
variant decreases the expression of GCG as a result of
splicing errors, resulting in low circulating glucagon and
GLP-1 levels. Therefore, we re-invited the homozygous
carriers of this variant and matched control individuals for
an additional OGTT and a combined glucose and arginine
stimulation test. The new investigations took place 10 years
after the first OGTT in these volunteers. Indeed, we found
that homozygous carriers of the rare G allele of rs4664447
had approximately half the fasting and stimulated circulat-
ing levels of GLP-1, glucagon and insulin compared with
matched wild-type carriers. The GG carriers had increased
insulin sensitivity as calculated by HOMA-IR and Matsu-
da’s index, respectively, while the disposition index was
similar between the genotype groups. Thus, although GG
carriers had severely decreased fasting and stimulated
serum insulin levels, the insulin response was adequate
for the level of insulin sensitivity, indicating a normal beta
cell function with retained capacity to adapt to changes in
insulin sensitivity. This interpretation of data also corre-
sponds with the lack of an association of the variant with
type 2 diabetes. Rather, the low serum insulin levels in the
homozygous carriers may be viewed as a compensatory
mechanism resulting from the low levels of glucagon.
Indeed, it has been shown that endogenously released
glucagon may determine the cAMP production in beta cells
Fig. 3 Fully processed plasma glucagon and serum insulin levels
during a glucose-dependent arginine stimulation test. a Fully
processed plasma glucagon levels, pAUC=0.0004. b Serum insulin
levels, pAUC=0.007. Black circles: mutation carriers (rs4664447 GG),
n=3; white squares: non-mutation carriers (rs4664447 AA) who are
BMI, age and sex matched controls (wild-types), n=9. The blood
glucose was stabilised and maintained at 14 and 25 mmol/l for 45 min
prior to and 30 min after arginine injection (arrow). Blood samples
were drawn at −15, −10, −5, +2, +4, +6, +10, +15, and +30 min
relative to arginine injection. There was a 2.5 h resting period without
glucose infusion in between the clamps at 14 and 25 mmol/l glucose
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and thereby the insulin secretion [22]. The low fasting
plasma glucose can also directly be explained by the
decreased circulating glucagon levels causing decreased
glycogenolysis and gluconeogenesis. In agreement with this
concept, the GCG knockout mouse manifests with lower
blood glucose and lower serum insulin levels, as well as
higher insulin sensitivity, compared with wild-type mice
[23]. The lower height among homozygous carriers compared
with wild-type carriers may be due to the low serum insulin
levels with reduced anabolic effects of insulin, probably
starting in the fetus. It should be noted that the potential
functionality of the intronic rs4664447 is predicted based on
bioinformatics analysis and in vivo physiological associa-
tions. Obviously, future studies should attempt to validate
Table 4 Associations of rs4664447 in GCG with metabolic traits during glucose-dependent arginine stimulation test
rs4664447 AA GG p value
Participants (men/women) 9(6/3) 3(2/1)
Age (year) 54±7 55±9
BMI (kg/m2) 24.7±3.3 24.2±3.1 0.2
Serum insulin 0 min (pmol/l) 27±8 11±4 0.002
Plasma glucose 0 min (mmol/l) 5.9±0.5 5.6±0.5 0.5
HOMA-IR 7.2±2.7 2.6±1.8 0.002
Fasting AIR0–10arginine (pmol/l×min) 2,208±501 1,265±157 0.0006
Clamp 14 mmol/l glucose AIR0–10arginine (pmol/l×min) 9,636±3,370 6,118±1,600 0.04
Clamp 25 mmol/l glucose AIR0–10arginine (pmol/l×min) 11,510±3,562 7,592±916 0.02
Disposition index (fasting AIR0–10arginine/HOMA-IR) 357±157 558±321 0.4
Data are mean±SD
AIR0–10arginine is the AIR following arginine stimulation (0–10 min)
Table 5 Anthropometric data stratified on Ile158Val, rs4664447 and rs7581952 of GCG in the combined study sample of 17,584 Danes
GCG variant Participants (men/women) Age (years) BMI (kg/m2) Body weight (kg) Waist circumference (cm) Height (cm)
Ile158Val
IleIle 17,320 (9,190/8,130) 55±11 27.8±5 82±17 93±15 171±9
IleVal 69 (33/36) 57±11 27.8±4.1 80±13 93±13 170±8
ValVal 2 (2/0) 58±14 33.6±6.4 103±24 114±19 174±4
pdom 0.8 0.7 0.9 0.2
rs4664447
AA 16,771(8,879/7,892) 55±11 27.8±5 82±17 93±15 171±9
GA 797(413/384) 55±11 27.6±5.2 81±17 92±15 171±10
GG 14(10/4) 54±15 26.7±6.8 71±16 94±18 168±9
padd 0.2 0.02 0.02 0.1
pdom 0.2 0.04 0.02 0.2
prec 0.4 0.004 0.8 0.003
rs7581952
TT 16,754 (8,910/7,844) 55±11 27.8±5.1 82±17 94±15 171±9
TG 792 (415/377) 55±11 27.5±5.0 81±17 92±15 171±10
GG 11(6/5) 58±17 26.4±5.8 76±16 93±16 170±8
padd 0.04 0.03 0.009 0.4
pdom 0.04 0.03 0.009 0.5
prec 0.3 0.2 0.6 0.3
Data are mean±SD
The actual number of individuals genotyped for each variant is stated in the table
p values were calculated for additive (padd), dominant (pdom), and recessive models (prec), except for Ile158Val, which only could be calculated in a
dominant model due to low frequency. Adjustments were made for the effect of age and sex
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these findings in appropriate in vitro assays. We attempted to
replicate these findings by applying a recessive genetic model
in DIAGRAM+ and in MAGIC meta-analyses. However,
both DIAGRAM and MAGIC only provide meta-analysis
data from additive models. Furthermore, in DIAGRAM the
variant failed a cohort-specific quality check; this is likely to
be the case for several low frequency variants. In accordance
with our findings using an additive model, there were no
significant additive associations in MAGIC, because only the
phenotypes of homozygous carriers of the low frequency G
allele were different from AA and AG carriers.
Carriers of the Val allele of the Ile158Val variant had
nearly twice as high a risk of type 2 diabetes as compared
with Ile allele carriers. However, as the association of
Ile158Val with type 2 diabetes is borderline significant, it
would not pass any correction for multiple testing. Therefore
we performed functional analyses of this mutant GLP-2
peptide. However, both in functional receptor analyses and in
intestinotrophic effect analyses, there was no significant
difference between the properties of wild-type GLP-2 and
[Ile158Val]-GLP-2. Thus, we consider the association
between Ile158Val and type 2 diabetes as a chance finding.
Ile158Val IleIle IleVal pdom
Alleles (men/women) 5,785 (2,724/3,061) 20 (12/8)
Age (years) 46.1±7.9 45.7±7.2
Height (cm) 172±9 173±9 0.4
Weight (kg) 78.1±16 74.8±10.6 0.01
BMI (kg/m2) 26.2±4.6 25.2±3.3 0.3
Waist circumference (cm) 86.6±13.4 84.7±8.8 0.2
Serum insulin 0 min (pmol/l) 42.9±29.8 34.8±22.2 0.06
Serum insulin 30 min (pmol/l) 290.5±183.8 230.6±123.4 0.1
Serum insulin 120 min (pmol/l) 217.6±213.0 158.2±77.9 0.6
AUC for insulin (pmol/l) 22,917±15,962 16,687±7,979 0.06
Plasma glucose 0 min (mmol/l) 5.6±1.1 5.8±2.2 0.6
Plasma glucose 30 min (mmol/l) 8.7±1.9 9.1±3.1 0.6
Plasma glucose 120 min (mmol/l) 6.2±2.1 6.8±4.2 0.4
HOMA-IR 11.1±10.0 9.3±7.1 0.1
Matsuda’s insulin sensitivity 9.0±5.6 9.5±4.5 0.3
Insulinogenic index 29.2±19.6 22.8±11.5 0.06
Disposition index 3.6±2.8 3.8±3.0 0.7
Table 6 Associations of
Ile158Val in GCG with meta-
bolic traits in treatment-naive
individuals from the Inter99
cohort
Data are mean±SD
p values were only possible to
calculate for a dominant model
(pdom). Calculated p values were
adjusted for sex, age and BMI
(when appropriate). Insulin and
glucose values were log10 trans-
formed before analysis
rs7581952 TT TG GG pdom
Alleles (men/women) 5,494 (2,720/2,774) 265 (130/135) 2(1/1)
Height (cm) 172±9 172±10 171±10 0.8
Weight (kg) 78.1±16 77.6±16.1 77.7±0.7 0.5
BMI (kg/m2) 26.2±4.5 26.0±4.7 25.7±3.5 0.5
Waist circumference (cm) 86±13 86±12.82 85±2.8 0.9
Serum insulin 0 min (pmol/l) 41.8±27.8 42.6±27.6 24±12.7 0.7
Serum insulin 30 min (pmol/l) 289.4±178.7 296.4±191.5 140.5±47.3 0.6
Serum insulin 120 min (pmol/l) 216.8±211.2 214.7±209.9 98±8.4 0.8
AUC for insulin (pmol/l) 22,853±15,716 23,166±15,247 10,320±1,887 0.7
Plasma glucose 0 min (mmol/l) 5.5±0.8 5.6±0.7 5.2±0.5 0.2
Plasma glucose 30 min (mmol/l) 8.6±1.8 8.7±1.9 7.8±0.4 0.9
Plasma glucose 120 min (mmol/l) 6.2±2.1 6.2±1.8 5.1±1.0 0.6
HOMA-IR 10.5±7.9 10.8±7.9 5.3±2.3 0.5
Matsuda’s insulin sensitivity 9.0±5.6 8.9±5.4 15.9±6.4 0.7
Insulinogenic index 29.2±19.0 29.8±21.0 15.01±5.36 0.4
Disposition index 3.6±2.8 3.7±3.1 3.8±3.9 0.7
Table 7 Associations of
rs7581952 in GCG with
metabolic traits in treatment-
naive individuals from the
Inter99 cohort
Data are mean±SD
p values were only possible to
calculate for a dominant model
(pdom). Calculated p values were
adjusted for sex, age and BMI
(when appropriate). Insulin and
glucose values were log10 trans-
formed before analysis
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The phenotype of carriers of the G allele of GCG
rs7581952 was characterised by lower BMI, body weight,
and waist circumference as compared with T allele carriers.
The BMI was decreased by 1.4 BMI units for GG allele
carriers compared with TTallele carriers in 17,557 Danes. We
attempted to replicate the findings of decreased BMI for GG
carriers. However, in the GIANT meta-analysis there was no
significant additive decreased BMI for G allele carriers.
Thus, we conclude that our initial findings are spurious.
The Trp169Ter variant did not co-segregate with measures
of obesity or diabetes although the mutation causes a
transcriptional termination of nine amino acids from the C-
terminal end of GLP-2. This will properly disrupt the action of
the peptide. As the mutation was found in the heterozygous
form only and no obvious phenotype was seen, one normal
allele may be sufficient for synthesis of adequate amounts of
GLP-2 to obtain its normal physiological function.
We did not find any presumably functional GCG
mutation that co-segregated with early-onset non-
autoimmune diabetes or early-onset obesity, suggesting that
the GCG variants discovered may not be involved in the
pathogenesis of monogenic forms of diabetes or obesity.
This indicates that genetic variation in GCG will have no
major impact on clinical practice.
Our study has limitations. One is that the variants that
were chosen for the large-scale association studies were
selected based on in silico information in combination with
phenotypes of carriers, which leaves the possibility that
non-selected variants also associate with metabolic traits.
Second, even though the statistical power to detect the
large differences in circulating insulin, GLP-1 and glucagon
levels between GCG rs4664447 variant carriers was above
80%, it was only possible to perform the OGTT and
hyperglycaemic arginine stimulation studies in three GG
carriers compared with nine AA carriers. This illustrates the
difficulties of providing proof of concept of functionality of
recessive-acting low frequency variants.
Furthermore, when Bonferroni correction for multiple
testing was applied, only p values of 0.001 or less were
considered significant. Thus, these suggestive results need
to be replicated in independent large-scale studies, where it
is possible to apply recessive models on directly genotyped
data. At present the relevant GWAS meta-analysis data are
not suitable for replication of low frequency variants
analysed for recessive models.
In conclusion, if replicated, the present biological
candidate gene study in Danish individuals suggests that
homozygous minor allele carriers of the low frequency
GCG rs4664447 variant have significantly decreased fast-
ing and stimulated circulating levels of insulin, glucagon
and GLP-1. Overall, our findings suggest that variation in
GCG has no major impact on carbohydrate metabolism in
the study populations examined.
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